By Editorial TeamThe chronic disease epidemic is crushing our healthcare systems. The old model of reacting to problems with intermittent check-ups is failing, and it’s failing badly. A new approach is taking shape, one based on continuous algorithmic management where AI infrastructure connects what’s found in a diagnostic scan directly to a patient’s long-term care plan. For investors, the most important thing to understand is how this plumbing is being built, especially how companies are creating proprietary data assets. That’s how you spot tomorrow’s category leaders.
Inflection Points and the Rise of AI-Native Chronic Disease Infrastructure
We’re at a major inflection point, the kind that creates entirely new markets, because of the collision between widespread digital health data, powerful machine learning, and the urgent need for better chronic care. Moving from one-off visits to continuous management for conditions like cardiovascular disease, diabetes, and cancer requires platforms that can ingest and act on a constant stream of patient data. This takes more than a few clever algorithms. It demands a foundational infrastructure built to be AI-native from the ground up, where the product, the data pipeline, and the business model are all woven together with AI. The platforms that will become the most valuable are the ones building proprietary data flywheels. This is about creating a “data moat”, a competitive advantage built from unique, hard-to-copy datasets that constantly make their AI models smarter. The real work isn’t just collecting terabytes of data. It’s about structuring, labeling, and integrating that data in a clinical setting to generate the real-world evidence (RWE) that proves the technology works and guides what to build next.
Constructing the Data Pipelines: Lessons from Leading Platforms
If you look at the companies building infrastructure for AI in chronic disease, a clear pattern emerges. Success depends entirely on building strong, longitudinal data pipelines. This is the new “Founder Playbook”: create a proprietary data asset you own.
Viz.ai: Orchestrating Chronic Vascular Care Coordination
Viz.ai is a great example of this playbook in chronic vascular care. Most people know them for their acute stroke triage software, but their long-term goal is to manage the entire care journey for patients with chronic vascular conditions. Their platform connects diagnostic insights, like spotting an incidental pulmonary embolism on a routine CT scan, directly to the next steps in patient management. It orchestrates the follow-up appointments and coordinates between specialists. The infrastructure Viz.ai built pulls in a continuous stream of data from imaging systems, EHRs, and other clinical sources, which gives their AI models the context to understand a finding’s severity within a patient’s history. It works. A single-center study showed its Viz Pulmonary Suite slashed the time to treatment for high-risk PE patients from 1.75 days to 0.56 days. Currently deployed in 2,000 hospitals across the United States and serving an estimated 230 million patients with over 50 AI care pathways, the scale is impressive. The company also holds 13 FDA clearances, including the first-ever de novo clearances for AI Computer Aided Triage and ECG-based cardiovascular management software. That kind of efficiency directly improves patient outcomes when every second counts. For investors, Viz.ai’s value is in the proprietary, real-world data it generates on patient pathways, which it uses to constantly refine its algorithms and expand into new use cases.
Tempus AI: Building Longitudinal Oncology and Neuropsychiatry Data Pipelines
Tempus AI’s whole mission is to build the data plumbing for precision medicine, especially in oncology and neuropsychiatry. Their method is to create complete, long-term patient records by pulling together molecular, clinical, and imaging data. This is a massive effort, involving the curation of data from roughly 38 million research records and over 7 billion clinical notes to create an enormous real-world evidence database. Tempus AI’s datasets contain genomic sequencing data, physician notes, pathology reports, and treatment outcomes. Having this much longitudinal data lets their AI models find subtle patterns, predict how a patient will respond to a certain therapy, and in the end shape personalized strategies for diseases like cancer. They’ve also received FDA 510(k) clearance for Tempus ECG-PH, their third AI cardiovascular device, which identifies signs of pulmonary hypertension from a standard 12-lead ECG. The sheer scale of Tempus’s data assets creates a powerful moat that is almost impossible for competitors to replicate. Their clinical value is on full display in their many peer-reviewed publications on Tempus’s RWE database. For investors, Tempus is a long-term bet on the foundational data layer that personalized, AI-driven medicine can’t exist without.
Paige AI: Enabling Oncology Diagnostics Infrastructure
Paige AI, which Tempus AI acquired in August 2025, now forms a core piece of Tempus’s diagnostics infrastructure, focusing on computational pathology. Its AI models help pathologists by analyzing digital slides to detect cancer, grade tumors, and find biomarkers. Though it starts with a diagnosis, the infrastructure Paige is building is perfectly suited for long-term chronic disease management. For instance, after Paige Prostate Detect received FDA De Novo marketing authorization in 2021, Tempus launched Paige Predict in January 2026 which uses the platform to predict biomarkers from H&E images in different cancers. By turning pathology into structured, computable data (a huge leap from the old analog process), Paige AI creates information that feeds directly into longitudinal patient records. This allows for much more precise prognostication and treatment planning in oncology. This feedback loop, where AI-assisted diagnosis informs treatment and tracks outcomes, continuously enriches their proprietary data and makes the models better over time.
The Investor Takeaway: Proprietary Data Flywheels as the Ultimate Moat
The companies that will own the future of AI-driven chronic disease management are the ones building proprietary data flywheels. It’s not about having “big data.” It’s about having clinically relevant, outcomes-oriented, and continuously updated data that makes AI models more accurate. So how do you pick the winners? Investors and VCs in this space have to look past the superficial AI claims. They need to dig deep into how these companies are getting, cleaning, and using their data. They should be asking about the strategy for generating real-world evidence, the regulatory pathways (especially for SaMD and PCCPs), and the hard proof of improved patient outcomes and healthcare savings. The ability to build and constantly enrich a proprietary data asset is the only real moat in this sector, and it’s the clearest signal of a strong, defensible business. This analysis of the leading digital health platforms shows that the true value isn’t in the AI algorithms alone. It’s in the carefully built data pipelines that feed them, making continuous, longitudinal chronic care a reality. Clinical studies on longitudinal chronic care outcomes Platform engagement metrics in chronic disease management.
Frequently Asked Questions
What is the primary investment opportunity in AI for chronic disease management?
The primary investment opportunity lies in AI-native platforms that redefine chronic care delivery through continuous algorithmic management. These platforms connect diagnostic insights to long-term patient management, fostering proactive, personalized care. Investors should focus on companies building proprietary data assets to create competitive advantages.
What defines a ‘data moat’ in this context and why is it important?
A ‘data moat’ is a competitive advantage derived from unique, difficult-to-replicate datasets that continuously improve AI model performance. It is important because it involves structuring, labeling, and integrating data in a clinical context to generate real-world evidence (RWE), validating efficacy and driving further product development, making it hard for competitors to catch up.
How do leading platforms like Viz.ai and Tempus AI exemplify the creation of proprietary data assets?
Viz.ai ingests continuous data from imaging systems and EHRs to orchestrate chronic vascular care, refining algorithms with real-world data on patient pathways. Tempus AI builds comprehensive, longitudinal data records by integrating molecular, clinical, and imaging data from millions of research records and billions of clinical notes, creating unparalleled RWE databases in oncology and neuropsychiatry.
What are the key characteristics of an ‘AI-native’ chronic care platform?
An AI-native chronic care platform is designed from inception with its core product, data pipeline, and business model intrinsically linked to AI. It is capable of ingesting, analyzing, and acting on continuous patient data streams, moving beyond episodic interventions to provide continuous, proactive care.
